BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 10721503)

  • 1. Automated docking and molecular dynamics simulations of nimesulide in the cyclooxygenase active site of human prostaglandin-endoperoxide synthase-2 (COX-2).
    García-Nieto R; Pérez C; Gago F
    J Comput Aided Mol Des; 2000 Feb; 14(2):147-60. PubMed ID: 10721503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular modelling of the differential interaction between several non-steroidal anti-inflammatory drugs and human prostaglandin endoperoxide H synthase-2 (h-PGHS-2).
    Pouplana R; Lozano JJ; Ruiz J
    J Mol Graph Model; 2002 Jan; 20(4):329-43. PubMed ID: 11858641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural basis for selective inhibition of COX-2 by nimesulide.
    Fabiola GF; Pattabhi V; Nagarajan K
    Bioorg Med Chem; 1998 Dec; 6(12):2337-44. PubMed ID: 9925294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale for the observed COX-2/COX-1 selectivity of celecoxib from Monte Carlo simulations.
    Price ML; Jorgensen WL
    Bioorg Med Chem Lett; 2001 Jun; 11(12):1541-4. PubMed ID: 11412976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular model of the interaction between nimesulide and human cyclooxygenase-2.
    García-Nieto R; Pérez C; Checa A; Gago F
    Rheumatology (Oxford); 1999 May; 38 Suppl 1():14-8. PubMed ID: 10369401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structure-based QSAR study on differential inhibition of human prostaglandin endoperoxide H synthase-2 (COX-2) by nonsteroidal anti-inflammatory drugs.
    Pouplana R; Lozano JJ; Pérez C; Ruiz J
    J Comput Aided Mol Des; 2002 Oct; 16(10):683-709. PubMed ID: 12650588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docking studies on NSAID/COX-2 isozyme complexes using contact statistics analysis.
    Ermondi G; Caron G; Lawrence R; Longo D
    J Comput Aided Mol Des; 2004 Nov; 18(11):683-96. PubMed ID: 15865061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion of prostaglandin G/H synthase-1 into an enzyme sensitive to PGHS-2-selective inhibitors by a double His513 --> Arg and Ile523 --> val mutation.
    Wong E; Bayly C; Waterman HL; Riendeau D; Mancini JA
    J Biol Chem; 1997 Apr; 272(14):9280-6. PubMed ID: 9083063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural approach for COX-2 inhibition.
    Michaux C; Charlier C
    Mini Rev Med Chem; 2004 Aug; 4(6):603-15. PubMed ID: 15279594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of arginine 120 of human prostaglandin endoperoxide H synthase-2 in the interaction with fatty acid substrates and inhibitors.
    Rieke CJ; Mulichak AM; Garavito RM; Smith WL
    J Biol Chem; 1999 Jun; 274(24):17109-14. PubMed ID: 10358065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2.
    Luong C; Miller A; Barnett J; Chow J; Ramesha C; Browner MF
    Nat Struct Biol; 1996 Nov; 3(11):927-33. PubMed ID: 8901870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Studied on docking of 5,6-diaryl-2,3-dihydro-1-pyrrolizinone derivatives with cyclooxygenase].
    Zhao LQ; Hu YD; Yuan Y; Zhang T; Zhang SF; Li S
    Yao Xue Xue Bao; 2001 Jun; 36(6):415-8. PubMed ID: 12585123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors.
    Gierse JK; McDonald JJ; Hauser SD; Rangwala SH; Koboldt CM; Seibert K
    J Biol Chem; 1996 Jun; 271(26):15810-4. PubMed ID: 8663121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative molecular modeling study of the three-dimensional structures of prostaglandin endoperoxide H2 synthase 1 and 2 (COX-1 and COX-2).
    Filizola M; Perez JJ; Palomer A; Mauleón D
    J Mol Graph Model; 1997 Oct; 15(5):290-300. PubMed ID: 9640560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of Tyr504 as an alternative tyrosyl radical site in human prostaglandin H synthase-2.
    Rogge CE; Liu W; Wu G; Wang LH; Kulmacz RJ; Tsai AL
    Biochemistry; 2004 Feb; 43(6):1560-8. PubMed ID: 14769032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of celecoxib and rofecoxib analogues as selective cyclooxygenase-2 (COX-2) inhibitors: replacement of sulfonamide and methylsulfonyl pharmacophores by an azido bioisostere.
    Habeeb AG; Praveen Rao PN; Knaus EE
    J Med Chem; 2001 Aug; 44(18):3039-42. PubMed ID: 11520213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The structures of prostaglandin endoperoxide H synthases-1 and -2.
    Garavito RM; Malkowski MG; DeWitt DL
    Prostaglandins Other Lipid Mediat; 2002 Aug; 68-69():129-52. PubMed ID: 12432914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions of some PGHS-2 selective inhibitors with the PGHS-1: an automated docking study by BioDock.
    Pedretti A; Villa AM; Villa L; Vistoli G
    Farmaco; 1997; 52(6-7):487-91. PubMed ID: 9372601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential binding mode of diverse cyclooxygenase inhibitors.
    Llorens O; Perez JJ; Palomer A; Mauleon D
    J Mol Graph Model; 2002 Mar; 20(5):359-71. PubMed ID: 11885959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cyclooxygenase-2 structure: new drugs for an old target?
    Garavito RM
    Nat Struct Biol; 1996 Nov; 3(11):897-901. PubMed ID: 8901861
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.